You are here
Professor Phil Sutton
Professor Phil Sutton moved to the Murdoch Children's Research Institute in 2012 where he leads the Mucosal Immunology group.
Phil studied Biomedical Science at Bradford University in the UK before completing a PhD in Immunology at Manchester University. He moved to Australia in 1992 for his first postdoctoral position, and apart from a brief spell at Institut Pasteur de Lille in France, has been here ever since.
Professor Sutton has extensive experience in academia and industry, including a period as Immunology Group Leader within the R&D division of CSL Limited. During his 30 years' in research, he has applied immunology to such fields as organ transplantation, fungal pathogenesis, parasitology, bacterial pathogenesis, vaccine adjuvant technologies, the design of novel vaccines against specific pathogens and host regulation of inflammatory diseases.
Phil and his research group at MCRI have a particular interest in how specific host factors contribute to susceptibility or resistance to diseases, and how these might be targeted to develop new therapies and strategies that allow the development of vaccines with improved effectiveness against mucosal pathogens.
The main areas of research performed by the Mucosal Immunology Group include examining how immunity at mucosal surfaces protect against pathogenic infection, studying how the host regulates chronic inflammation caused by mucosal pathogens and the development of novel vaccine strategies against major disease-causing bacteria.
Inflammation caused by infection with the bacterium Helicobacter pylori is the main cause of stomach and duodenal ulcers, and gastric cancer, while infections in the lungs of children with cystic fibrosis cause chronic inflammation that is an important driver of disease progression. The progression of such diseases is highly complex and differs between individuals due to many factors, including variations in the pathogens, environmental effects, and genetic factors that can play significant roles in determining if someone is more or less susceptible to disease development.
The Mucosal Immunology Group is working to understand how specific host factors contribute to susceptibility or resistance to diseases such as cystic fibrosis and those related to H. pylori infection, so that these factors might be targeted to develop new therapies. The group is also interested in strategies that allow the development of vaccines against mucosal pathogens or that might prevent the diseases which these infections cause.
- Developing an immunotherapeutic approach to protect against Helicobacter pylori associated diseases including stomach cancer
- Exploring a novel drug treatment for preventing H. pylori associated diseases
- Studying the mucosal immune response in cystic fibrosis
- Developing a novel vaccine against an important pathogen in cystic fibrosis
Stent A, Every A, Chionh Y, Ng G & Sutton P. (2018) Superoxide dismutase from Helicobacter pylori suppresses the production of pro-inflammatory cytokines during in vivo infection. Helicobacter 23: e12459
Dhar P, Ng G, Dunne E & Sutton P. (2017) Mucin1 protects against severe Streptococcus pneumoniae disease. Virulence 8: 1631-1642
Saeed M, Ng G, Dabritz J, Wagner J, Judd L, Han J, Dhar P, Kirkwood C & Sutton P. (2017) Protease-activated receptor 1 plays a pro-inflammatory role in colitis by promoting Th17-related immunity. Inflammatory Bowel Diseases 23:593-602.
Menheniott T, O'Connor L, Chionh Y, Däbritz J, Rollo B, Ng G, Jacobs S, Catubig A, Scurr M, Kurklu B, Mercer S, Minamoto T, Ong D, Ferrero R, Fox J, Wang T, Sutton P, Judd L & Giraud A. (2016) Loss of Gastrokine-2 drives premalignant inflammation and tumor progression in gastric cancer. Journal of Clinical Investigation 126: 1383-1400.
Han J, Ng G, Cecchini P, Chionh Y, Saeed M, Naess L, Joachim M, Blandford L, Strugnell R, Colaco C & Sutton P. (2016) Heat shock protein complex vaccines induce antibodies against Neisseria meningitidis via a MyD88-independent mechanism. Vaccine 34: 1704-1711.
Ng G, Menheniott T, Every A, Stent A, Judd L, Chionh Y, Dhar P, Komen J, Giraud A, Wang T, McGuckin M & Sutton P. (2016) The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome. Gut 65: 1087-1099.
Chionh Y, Ng G, Ong L, Arulmuruganar A, Stent A, M Saeed, Wee J & Sutton P. (2015) Protease Activated Receptor 1 suppresses Helicobacter pylori gastritis in mice via the inhibition of macrophage cytokine secretion and Interferon Regulatory Factor 5. Mucosal Immunology 8: 68-79.
Sutton P. (2015) At last, vaccine-induced protection against Helicobacter pylori. Lancet 386: 1424-1425
Chionh Y, Arulmuruganar A, Venditti E, Ng G, Han J, Ang C, Entwisle C, Colaco C, McNulty S & Sutton P. (2014) Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Vaccine 32: 2350–2358
McGuckin M, Linden S, Sutton P & Florin T. (2011) Mucin Dynamics and Enteric Pathogens. Nature Reviews Microbiology 9: 265-278
Wee J, Chionh Y-T, Ng G, Harbour S, Allison C, Pagel C, Mackie E, Mitchell H, Ferrero R & Sutton P (2010) Protease Activated Receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori . Gastroenterology 138: 573–582